The Oculis strategy is to build an innovative ophthalmology company unlike any other. Our plan is to:
OCS-01, our most advanced product candidate based on OPTIREACH technology, has recently completed two Phase 2 studies, one in DME and one in Pain and Inflammation following cataract surgery. The study in DME is the first proof-of-concept of a topical drug effect on retinal edema and is also a successful proof-of-concept for the OPTIREACH formulation technology. If approved in DME, it has the potential to provide a new option for patients whose current therapies are limited to intravitreal injections or implants. The study in post-cataract surgery is the first proof-of-concept of a once daily topical steroid for treating Inflammation and Pain following ocular surgery. OCS-01 is moving into phase III, following a positive End of Phase 2 meeting, in both indications.
Our novel OPTIREACH formulation technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants